Mazdutide: Evidence, Mechanism, Dosing & Legal Status

Mazdutide is a synthetic, acylated analog of oxyntomodulin (OXM) — a natural gut hormone — engineered for once-weekly subcutaneous dosing as a treatment for obesity and type 2 diabetes.14 It carries the developer codes IBI362 (Innovent Biologics) and LY3305677 (Eli Lilly), reflecting its co-development.15 Unlike most peptides covered in this encyclopedia, its evidence base is mature human trial data, not preclinical extrapolation. This monograph separates what is proven from what remains uncertain.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Mazdutide is a prescription drug — approved in China and investigational in the US — and is not FDA-approved. Dosing figures are reported strictly as seen in the published literature and clinical trials for completeness, not as recommendations. Consult a licensed clinician before any health decision.

What is mazdutide and how does it work?

Mazdutide is an analog of oxyntomodulin, a naturally occurring gut hormone that intrinsically activates both the GLP-1 and glucagon receptors.14 To convert the short-lived native peptide into a once-weekly drug, several engineering modifications were made: the position-2 serine was substituted with aminoisobutyric acid (Aib) to resist DPP-4 cleavage; methionine-27 was substituted with leucine to remove an oxidation liability; the helical topology was stabilized with a bifurcated salt bridge; and a fatty-acyl moiety was added to drive albumin binding and extend half-life.1516

The defining feature is dual receptor engagement. Unlike single-target GLP-1 agonists (semaglutide, liraglutide) or the GLP-1/GIP co-agonist tirzepatide, mazdutide activates both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR), with reported in-vitro binding affinities of approximately Ki 17.7 nM at GLP-1R and 28.6 nM at GCGR.15 The GLP-1 arm suppresses appetite, augments glucose-dependent insulin secretion, and slows gastric emptying; the glucagon arm adds thermogenesis, hepatic fatty-acid oxidation, and direct lipolysis — which the developers credit for the unusually large hepatic-fat reductions seen in trials.111 From a functional, root-cause lens, this is mechanistically attractive because it targets both energy intake and energy expenditure plus hepatic lipid handling, rather than appetite alone — though the glucagon component is also why this class is monitored differently from pure GLP-1 drugs. In Phase 1b pharmacokinetics, single-dose exposure at 2.5–3 mg showed a median Tmax around 72 hours and a wide terminal half-life of roughly 7.3 to 44.8 days, long enough to support once-weekly administration.2

What is the evidence by indication?

Mazdutide's two best-evidenced uses — chronic weight management and glycemic control in type 2 diabetes — both rest on completed Phase 3 randomized controlled trials, grading to evidence level A.17 The trial program is largely China-based, organized as the GLORY obesity series and the DREAMS diabetes series.

The obesity evidence is the headline. GLORY-1 — a randomized, double-blind, placebo-controlled Phase 3 trial of 610 Chinese adults registered as NCT05607680 — randomized participants to mazdutide 4 mg, 6 mg, or placebo, given subcutaneously once weekly for 48 weeks.1 Mean body-weight change at week 48 was −12.05% (4 mg) and −14.84% (6 mg) versus −0.47% for placebo; ≥10% loss was reached by 55.2% and 67.9% of treated participants versus 2.9% on placebo.15 Hepatic fat content fell dramatically — in those with baseline ≥10%, by −65.85% (4 mg) and −80.24% (6 mg) versus −5.27% for placebo — alongside reductions in blood pressure, lipids, and uric acid.1 GLORY-2 then tested 9 mg and reported a mean 20.08% weight reduction at week 60 in the non-diabetic subgroup, with 48.7% achieving ≥20% loss and weight loss continuing through 60 weeks without plateau.6 Earlier Phase 1b and Phase 2 work established the dose-ranging that informed these doses.23

For type 2 diabetes, the DREAMS series is equally mature. DREAMS-1 reported HbA1c reductions of −1.58% (4 mg) and −2.02% (6 mg) versus −0.25% for placebo at week 24, and DREAMS-2 showed comparable or better control versus dulaglutide 1.5 mg.7 Most striking is DREAMS-3, a head-to-head Phase 3 against semaglutide 1 mg in 349 adults with T2D plus obesity over 32 weeks: mazdutide 6 mg achieved an HbA1c reduction of −2.03% versus −1.84% and weight loss of 10.29% versus 6.00%, and the composite primary (HbA1c <7% and ≥10% weight loss) was met by 48.0% versus 21.0% — a statistically significant superiority on the combined endpoint.89 A US high-dose Phase 1 adds limited non-Chinese pharmacokinetic and safety data.4

What doses appear in the literature?

Reported strictly as information, not a protocol. Mazdutide is given by subcutaneous injection once weekly, a schedule supported by its 7.3-to-44.8-day terminal half-life.12 Maintenance doses studied were 4 mg, 6 mg, and 9 mg weekly: GLORY-1 used 4 mg and 6 mg over 48 weeks, GLORY-2 used 9 mg over 60 weeks, and ascending-dose work explored up to 10 mg.16 Trials used gradual dose escalation — for example 3 to 6 to 9 mg, or 2.5 to 5 to 7.5 to 10 mg, in roughly four-week steps — to mitigate gastrointestinal adverse events, the standard incretin-class ramp.2 The approved Chinese indications cover chronic weight management in adults with BMI ≥28 (or ≥24 with at least one weight-related comorbidity) and glycemic control in adults with T2D.10 These figures describe the manufactured, clinically supervised drug as studied; lyophilized 'research-chemical' vendor vials are unapproved and are not a legitimate clinical product, so no reconstitution protocol is endorsed here.

How safe is mazdutide?

The most common adverse events are dose-dependent and mostly mild to moderate, concentrated during titration: nausea, vomiting, diarrhea, decreased appetite, and abdominal distension — the typical GLP-1-class gastrointestinal profile.2 In the small Phase 1b study, decreased appetite and nausea each affected up to about 62.5% of the 9 mg cohort, but all treatment-emergent events were mild or moderate with no serious adverse events and no AE-related discontinuations; Phase 3 (GLORY-1) confirmed the same class profile with low discontinuation and no signal of increased cardiovascular risk.21 Signals to watch include a heart-rate increase (up to ~+17 bpm acutely at 9 mg in Phase 1b, around +2.6 bpm at steady doses in GLORY-1), transient lipase elevation without pancreatitis, and immunogenicity, with anti-drug antibodies appearing in a minority of early participants including one neutralizing antibody to the glucagon-receptor activity.2

Because glucagon agonism can raise hepatic glucose output and influence lipid metabolism, the dual mechanism warrants attention to glycemia and hepatic function — even though trials showed net glucose lowering and hepatic-fat reduction, this is why the class is monitored differently from pure GLP-1 drugs.11 Class-level cautions, extrapolated from the GLP-1 class, include personal or family history of medullary thyroid carcinoma or MEN2, history of pancreatitis, gallbladder disease, severe gastrointestinal disease, and hypersensitivity. Delayed gastric emptying can alter absorption of oral co-medications, and combination with insulin or sulfonylureas raises hypoglycemia risk.2 There are no human safety data in pregnancy or lactation, so it should be treated as contraindicated absent specific clinical guidance.

What is the regulatory and anti-doping status in 2026?

In China, mazdutide is approved by the NMPA for chronic weight management (announced June 27, 2025) and for glycemic control in adults with type 2 diabetes (September 2025) — the world's first GCG/GLP-1 dual receptor agonist approved in either indication, with a 9 mg supplementary application for moderate-to-severe obesity under review.111012 In the United States it is not approved — it is investigational, with Eli Lilly holding US rights and running an obesity Phase 2; commentators project a possible FDA approval only after Phase 3, around 2028–2029, and there is no FDA label or DailyMed entry.11 Mazdutide sold as a research-only peptide labeled 'not for human use' is not FDA-approved, and using such material for human consumption falls outside lawful therapeutic use.18

For athletes, mazdutide is not individually listed on the WADA Prohibited List as of this writing, and metabolic or anti-obesity agents are not an established prohibited category. However, as a non-approved/investigational substance, off-label or non-approved use can implicate WADA category S0 (Non-Approved Substances); athletes should confirm current status and seek a Therapeutic Use Exemption where relevant.19

Bottom line. Mazdutide is one of the most de-risked compounds in this encyclopedia: Grade A human evidence supports both weight loss (~11–15% at 4–6 mg, up to ~20% at 9 mg) and glycemic control in T2D (HbA1c −1.6 to −2.0%), with a head-to-head Phase 3 edge over semaglutide and striking hepatic-fat reduction that plausibly reflects the glucagon arm. What remains uncertain is generalizability beyond the young, lower-BMI Chinese cohorts, long-term cardiovascular outcomes, and the implications of chronic glucagon agonism. Crucially, the legitimate evidence is for the manufactured, clinically supervised drug — not 'research-chemical' vials. Regulatory facts here are current as of June 2026 and should be re-verified, particularly any US FDA developments.